-
Longeveron Inc NasdaqCM:LGVN Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Location: Life Science & Technology Park, Miami, FL, 33136, United States | Website: https://longeveron.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.458M
Cash
19.23M
Avg Qtr Burn
-3.467M
Short % of Float
5.51%
Insider Ownership
7.70%
Institutional Own.
8.56%
Qtr Updated
12/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Lomecel-B (laromestrocel) Details Hypoplastic Left Heart Syndrome | Phase 2a Data readout | |
Lomecel-B (laromestrocel) Details Alzheimer's disease | Phase 2a Update | |
Lomecel-B Details Acute respiratory distress syndrome | Failed Discontinued | |
Lomecel-B Details Aging Frailty | Failed Discontinued |